#USA #Robbins Geller #San Diego #Baxter International #Baxter lawsuit

Baxter International Investors Urged to Act

The law firm Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors who purchased or acquired shares of Baxter International, Inc. (NYSE: BAX) between February 23, 2022, and July 30, 2025. Investors who have incurred substantial losses during this period are encouraged to step forward and pursue leading roles in a potential class action lawsuit against the company.

Important Deadlines

The deadline to seek appointment as lead plaintiff is December 15, 2025. The lawsuit, titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., raises serious allegations against Baxter and certain high-profile executives for violations of the Securities Exchange Act of 1934.

Allegations Against Baxter

According to the lawsuit, Baxter International's Novum IQ Large Volume Pump (Novum LVP) was plagued by systemic defects, leading to various malfunctions. These issues, which included underinfusion, overinfusion, and total non-delivery of fluids, posed serious risks to patient safety, with potential consequences ranging from serious injury to death. It is alleged that Baxter was made aware of multiple device malfunctions and injuries from these defects yet failed to take effective action.

Moreover, when Baxter attempted to respond through customer alerts, these measures were considered inadequate, as design flaws persisted and continued to harm patients. On July 31, 2025, Baxter announced a voluntary pause on shipments and planned installations of the Novum LVP, exacerbating the situation and leading to a significant stock price drop of over 22%.

The Role of the Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Baxter's common stock within the specified Class Period may apply to become the lead plaintiff in this class action. The lead plaintiff typically holds the most substantial financial interest in the potential recovery and serves the group by directing the lawsuit.

Being appointed as the lead plaintiff enables better representation for all class members, while investors who do not wish to take on such a role can still participate in any recovery without the obligation to lead.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is known as one of the leading firms in the realm of securities fraud litigation, firmly established as a powerful advocate for investors. Recognized for its impressive track record in securing monetary relief for harmed investors, the firm was ranked #1 by ISS Securities Class Action Services for achieving the highest financial recoveries over the past five years, recovering over $2.5 billion in 2024 alone.

With a powerful team of 200 attorneys operating across 10 offices, Robbins Geller remains committed to fighting for investor rights. The firm has successfully obtained some of the largest securities class action recoveries in history, including the unprecedented $7.2 billion in the Enron securities litigation.

For more information, affected investors can visit Robbins Geller's website or reach out to attorneys J.C. Sanchez or Jennifer N. Caringal at 800-449-4900.

Investors with substantial losses should act promptly to ensure their voices are heard and to maximize their opportunities for recovery in this critical lawsuit against Baxter International.